XB-ART-58790
J Pharmacol Exp Ther
2021 Oct 01;3791:41-52. doi: 10.1124/jpet.120.000370.
Show Gene links
Show Anatomy links
A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use.
Myers SJ
,
Ruppa KP
,
Wilson LJ
,
Tahirovic YA
,
Lyuboslavsky P
,
Menaldino DS
,
Dentmon ZW
,
Koszalka GW
,
Zaczek R
,
Dingledine RJ
,
Traynelis SF
,
Liotta DC
.
???displayArticle.abstract???
We describe a clinical candidate molecule from a new series of glutamate N-methyl-d-aspartate receptor subunit 2B-selective inhibitors that shows enhanced inhibition at extracellular acidic pH values relative to physiologic pH. This property should render these compounds more effective inhibitors of N-methyl-d-aspartate receptors at synapses responding to a high frequency of action potentials, since glutamate-containing vesicles are acidic within their lumen. In addition, acidification of penumbral regions around ischemic tissue should also enhance selective drug action for improved neuroprotection. The aryl piperazine we describe here shows strong neuroprotective actions with minimal side effects in preclinical studies. The clinical candidate molecule NP10679 has high oral bioavailability with good brain penetration and is suitable for both intravenous and oral dosing for therapeutic use in humans. SIGNIFICANCE STATEMENT: This study identifies a new series of glutamate N-methyl-d-aspartate (NMDA) receptor subunit 2B-selective negative allosteric modulators with properties appropriate for clinical advancement. The compounds are more potent at acidic pH, associated with ischemic tissue, and this property should increase the therapeutic safety of this class by improving efficacy in affected tissue while sparing NMDA receptor block in healthy brain.
???displayArticle.pubmedLink??? 34493631
???displayArticle.pmcLink??? PMC8626636
???displayArticle.link??? J Pharmacol Exp Ther
???displayArticle.grants??? [+]
R44 NS071657 NINDS NIH HHS , R43 NS049666 NINDS NIH HHS , U44 NS071657 NINDS NIH HHS , R44 NS049666 NINDS NIH HHS , R35 NS111619 NINDS NIH HHS
Species referenced: Xenopus laevis
References [+] :
Abe,
Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain.
2005, Pubmed
Abe, Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. 2005, Pubmed
Addy, Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. 2009, Pubmed
Albers, Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. 2001, Pubmed
Auvin, Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome. 2020, Pubmed
Awad, Predicting Death After Thrombectomy in the Treatment of Acute Stroke. 2020, Pubmed
Blagrove, The incidence of unpleasant dreams after sub-anaesthetic ketamine. 2009, Pubmed
Bristow, Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder. 2017, Pubmed , Xenbase
Brown, 2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity. 2011, Pubmed
Buemi, Targeting GluN2B-containing N-Methyl-D-aspartate receptors: design, synthesis, and binding affinity evaluation of novel 3-substituted indoles. 2014, Pubmed
Bullock, An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. 1999, Pubmed
Carlson, Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage. 2020, Pubmed
Carter, Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. 1988, Pubmed
Chaperon, Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. 2003, Pubmed
Chenard, Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. 1991, Pubmed
Chenard, (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. 1995, Pubmed
Choi, Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. 1988, Pubmed
Crupi, Management of Traumatic Brain Injury: From Present to Future. 2020, Pubmed
Davies, A novel series of benzimidazole NR2B-selective NMDA receptor antagonists. 2012, Pubmed
De Vry, Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. 2003, Pubmed
Dey, 2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists. 2018, Pubmed
Diener, Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study. 2002, Pubmed
Farin, Lessons from epidemiologic studies in clinical trials of traumatic brain injury. 2004, Pubmed
Fischer, Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. 1997, Pubmed , Xenbase
Gladstone, Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. 2002, Pubmed
Guenego, Hypoperfusion intensity ratio correlates with angiographic collaterals in acute ischaemic stroke with M1 occlusion. 2020, Pubmed
Guscott, The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. 2003, Pubmed
Higgins, Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. 2003, Pubmed
Higgins, Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. 2005, Pubmed
Hill, Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. 2012, Pubmed
Jang, A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. 2004, Pubmed , Xenbase
Junge, The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. 2003, Pubmed
Karakas, Crystal structure of a heterotetrameric NMDA receptor ion channel. 2014, Pubmed
Katsura, Extra- and Intracellular pH in the Brain During Ischaemia, Related to Tissue Lactate Content in Normo- and Hypercapnic rats. 1992, Pubmed
Kew, A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. 1996, Pubmed
Kidwell, Trends in acute ischemic stroke trials through the 20th century. 2001, Pubmed
Koller, Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006. 2010, Pubmed
Kostakis, A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons. 2011, Pubmed , Xenbase
Labas, Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors. 2011, Pubmed
Layton, Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. 2006, Pubmed
Layton, Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists. 2011, Pubmed
Lees, Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. 2000, Pubmed
Li, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. 2010, Pubmed
Liverton, Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist. 2007, Pubmed
Longstreth, Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in King County, Washington. 1993, Pubmed
Makani, Endogenous alkaline transients boost postsynaptic NMDA receptor responses in hippocampal CA1 pyramidal neurons. 2007, Pubmed
Marcin, BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder. 2018, Pubmed
McCauley, NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. 2004, Pubmed
McIntyre, Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists. 2009, Pubmed
Merchant, A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. 1999, Pubmed
Michel, Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease. 2014, Pubmed
Michel, Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs. 2015, Pubmed
Miller, Analysis of Apparent Noncompetitive Responses to Competitive H(1)-Histamine Receptor Antagonists in Fluorescent Imaging Plate Reader-Based Calcium Assays. 1999, Pubmed
Mony, Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. 2009, Pubmed
Morris, Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. 1999, Pubmed
Mosley, Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. 2009, Pubmed , Xenbase
Mott, Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. 1998, Pubmed , Xenbase
Muir, Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. 2006, Pubmed
Mutch, Extracellular pH changes during spreading depression and cerebral ischemia: mechanisms of brain pH regulation. 1984, Pubmed
Narayan, Clinical trials in head injury. 2002, Pubmed
Nedergaard, Dynamics of interstitial and intracellular pH in evolving brain infarct. 1991, Pubmed
Nguyen, Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists. 2007, Pubmed
Nicholson, The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. 2007, Pubmed
Nutt, Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. 2008, Pubmed
Olney, Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. 1969, Pubmed
Patel, Hyperacute Management of Ischemic Strokes: JACC Focus Seminar. 2020, Pubmed
Petrovic, 20-oxo-5beta-pregnan-3alpha-yl sulfate is a use-dependent NMDA receptor inhibitor. 2005, Pubmed
Porter, Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. 1999, Pubmed
Preskorn, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. 2008, Pubmed
Regan, Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors. 2019, Pubmed , Xenbase
Rowland, Subanesthetic ketamine: how it alters physiology and behavior in humans. 2005, Pubmed
Sacco, Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. 2001, Pubmed
Saver, The 2012 Feinberg Lecture: treatment swift and treatment sure. 2013, Pubmed
Shkirkova, Frequency, Predictors, and Outcomes of Prehospital and Early Postarrival Neurological Deterioration in Acute Stroke: Exploratory Analysis of the FAST-MAG Randomized Clinical Trial. 2018, Pubmed
Smith, Changes in extra- and intracellular pH in the brain during and following ischemia in hyperglycemic and in moderately hypoglycemic rats. 1986, Pubmed
Steece-Collier, Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. 2000, Pubmed
Stroebel, A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. 2016, Pubmed , Xenbase
Swartjes, Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. 2011, Pubmed
Tahirovic, Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. 2008, Pubmed , Xenbase
Taniguchi, Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. 1997, Pubmed
Thum, Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands. 2018, Pubmed , Xenbase
Tong, Kinetics of activity-evoked pH transients and extracellular pH buffering in rat hippocampal slices. 2006, Pubmed
Traynelis, Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. 1998, Pubmed , Xenbase
Turner, Acute ischemic stroke: improving access to intravenous tissue plasminogen activator. 2020, Pubmed
Vicentic, Biochemistry and pharmacology of epitope-tagged alpha(1)-adrenergic receptor subtypes. 2002, Pubmed
Wang, pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH. 2014, Pubmed
Weaver, Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. 1997, Pubmed
Weaver, Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca(2+) accumulation and cell death. 2000, Pubmed
Weed, Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. 2016, Pubmed
Williams, Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. 1993, Pubmed , Xenbase
Wood, The NMDA receptor complex: a long and winding road to therapeutics. 2005, Pubmed
Yuan, Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. 2015, Pubmed
Yurkewicz, The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. 2005, Pubmed
Zhang, Delay-dependent impairment of spatial working memory with inhibition of NR2B-containing NMDA receptors in hippocampal CA1 region of rats. 2013, Pubmed